API | eflapegrastim

eflapegrastim (Rolvedon) Report issue

Biologics Recombinant protein Approved ^FDA

AACT PubChem

Active Ingredient History

NOW

Eflapegrastim, sold under the brand name Rolvedon among others, is a long-acting G-CSF analog developed by Hanmi Pharmaceutical and licensed to Spectrum Pharmaceuticals. Eflapegrastim is a leukocyte growth factor. It is used to reduce the risk of febrile neutropenia in people with non-myeloid malignancies receiving myelosuppressive anti-cancer agents. ^Wikipedia

Chemistry

SMILES: Missing data
InChIKey: Missing data
Mol. Mass: Missing data
ALogP: Missing data
ChEMBL Molecule:
eflapegrastim

More Chemistry

Pharmacology

Mechanism of Action:
- Granulocyte colony-stimulating factor receptor (Homo sapiens) ^UniProt
Multi-specific: No
Black Box: No
Availability: Prescription Only
Delivery Methods: Parenteral
Pro Drug: No

eflapegrastim

Organizations (4)

Research & Development (3)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Marketing (2)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Indications (6)

Approved Indications (2)

Febrile Neutropenia (approved 2022)

Neoplasms

Experimental Indications - Clinical Trial Phases 1-4 (5)

Breast Neoplasms (Phase 4)

Lymphoma (Phase 2)

Neoplasms (Phase 2)

Neutropenia (Phase 3)

Pharmacokinetics (Phase 1)

Overview

Highest Phase: Phase 4
# of Trials: 6
# of Trial Organizations: 3

Trials by Phase

Trial	Phase	Start Date	Organizations	Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue